Ubi Pharma Inc is a Taiwan-based company mainly engaged in development and manufacturing of protein drugs and special dosage-form drugs. The Company is engaged in research and development, manufacturing and sales of protein drugs and special dosage-form drugs, contract manufacturing of pharmaceuticals, and provision of contract research services.

Employees

Sector

Pharmaceuticals

More about the company

End-of-day quote Taipei Exchange 06/05/2024			5-day change	1st Jan Change
14.25 ^TWD	+1.79%		-.--%	-

13/08	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
27/04	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	168.32Cr 5.31Cr 4.57Cr 4.29Cr 3.92Cr 7.36Cr 505.05Cr 7.41Cr 51Cr 20Cr 256.1Cr 20Cr 19Cr 847.99Cr	P/E 2024	-9.63x	P/E 2025	-5.68x
Enterprise Value	197.21Cr 6.22Cr 5.35Cr 5.03Cr 4.59Cr 8.62Cr 591.73Cr 8.68Cr 60Cr 23Cr 300.06Cr 23Cr 23Cr 993.53Cr	EV / Sales 2024	3.58x	EV / Sales 2025	3.83x
Free-Float	27.79%	Yield 2024 *	-	Yield 2025	-

13/08	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
27/04	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12/25/12	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/25/30	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
13/24/13	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
18/24/18	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
11/23/11	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
21/23/21	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
15/22/15	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	CI
29/22/29	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
29/22/29	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
16/21/16	Medigen Vaccine Biologics : Taiwan rejects COVID vaccine candidate, president to get domestic shot	RE
16/21/16	Medigen Vaccine Biologics : Taiwan denies approval for UBI's COVID-19 vaccine candidate	RE

3 years	10	38.5
5 years	10	139.55
10 years	8.34	288.72

UBI Pharma Inc. Share Price

Stocks

6562

TW0006562002

Pharmaceuticals

Valuation : UBI Pharma Inc.

Latest news : UBI Pharma Inc.

Quotes and Performance

Price Extremes

Managers and Directors : UBI Pharma Inc.

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Jung Kuang Yang CEO	Chief Executive Officer	-	-
Meng Han Hsu DFI	Director of Finance/CFO	-	11/04/2016
Ying Yun Fan ADM	Chief Administrative Officer	-	01/03/2015

Director	Title	Age	Since
Ying Yun Fan BRD	Director/Board Member	-	30/06/2020
Yan Ning Kuo BRD	Director/Board Member	-	30/06/2020
Yao Hui Wei BRD	Director/Board Member	-	30/06/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
UBI PHARMA INC.	+1.79%	-.--%	-.--%	-57.96%	5.32Cr
ELI LILLY AND COMPANY	-1.67%	-7.32%	+57.19%	+108.53%	1,04700Cr
JOHNSON & JOHNSON	-0.70%	-2.49%	+49.52%	+64.66%	65TCr
ABBVIE INC.	+0.39%	-3.25%	+20.76%	+74.14%	45TCr
ROCHE HOLDING AG	-1.64%	-4.75%	+35.59%	+35.54%	35TCr
NOVARTIS AG	-0.39%	-2.76%	+21.39%	+38.01%	29TCr
ASTRAZENECA PLC	-1.19%	-2.21%	+1.53%	+11.51%	25TCr
AMGEN INC.	-0.48%	-3.07%	+49.95%	+67.83%	23TCr
NOVO NORDISK A/S	-1.05%	-2.29%	-19.91%	-54.10%	20TCr
GILEAD SCIENCES, INC.	+0.48%	-0.26%	+29.86%	+91.37%	18TCr
Average	-0.56%	-1.97%	+24.59%	+37.95%	36.59TCr
Weighted average by Cap.	-1.01%	-3.46%	+36.48%	+64.72%

	2024	2025
Net sales	54Cr 1.7Cr 1.46Cr 1.37Cr 1.25Cr 2.36Cr 161.68Cr 2.37Cr 16Cr 6.33Cr 82Cr 6.38Cr 6.24Cr 271.46Cr	51Cr 1.62Cr 1.4Cr 1.31Cr 1.2Cr 2.25Cr 154.36Cr 2.27Cr 16Cr 6.05Cr 78Cr 6.09Cr 5.96Cr 259.17Cr
Net income	-17Cr -55.03L -47.38L -44.49L -40.61L -76.3L -52Cr -76.84L -5.27Cr -2.05Cr -27Cr -2.07Cr -2.02Cr -88Cr	-30Cr -93.43L -80.44L -75.53L -68.95L -1.3Cr -89Cr -1.3Cr -8.95Cr -3.48Cr -45Cr -3.51Cr -3.43Cr -149.26Cr
Net Debt	25Cr 77.69L 66.89L 62.81L 57.33L 1.08Cr 74Cr 1.08Cr 7.44Cr 2.9Cr 37Cr 2.92Cr 2.85Cr 124.11Cr	29Cr 91.1L 78.44L 73.65L 67.23L 1.26Cr 87Cr 1.27Cr 8.73Cr 3.4Cr 44Cr 3.42Cr 3.35Cr 145.54Cr